Copy
LISAvienna e-Newsletter 02/2015 – Get Connected
View this email in your browser

e-Newsletter 02/2015

Dear readers,

Spring is about to start. Before enjoying the sound of buzzing bees, we invite you to have a look at what busy researchers and business people in Vienna have achieved in recent weeks. Please find selected hot news below and check out funding opportunities and event notes. For a more comprehensive overview, please visit www.LISAvienna.at.

With regards to the biotechnology and pharmaceutical industry: We are already looking forward to our business trip to Singapore and Shanghai in May!

For the medical device decision makers: See you at IN3 EuroMedtech in Vienna in June!

But for now, enjoy reading through our e-newsletter!

LISAvienna

NEWSFLASH

AIT joined consortium for early cancer diagnosis
The Austrian Institute of Technology joined the ‘Early Diagnosis Consortium’ (EDC), a collaboration between Cancer Research UK and Abcodia, focusing on biomarkers for early diagnosis of cancer.
AOP Orphan Pharmaceuticals announced progress of pivotal phase III trial PROUD-PV
Recruitment is completed for PROUD-PV to support global licensure of Ropeginterferon alfa 2b (AOP2014/P1101), a novel, long-acting, mono-pegylated Interferon for the treatment of Polycythemia Vera (PV).
Apeiron Biologics announced start of phase I trial with anti cancer therapy triggering immunological checkpoint blockade
APN401, based on the collection, stimulation and subsequent re-administration of a patient’s immune cells, is being investigated in a clinical phase I trial performed at a renowned medical center in the US.
Apeptico announced results of phase IIa clinical study of AP301-peptide
Apeptico announced that the phase IIa clinical study of the AP301-peptide delivered top-line results in the treatment of primary graft dysfunction in patients following lung transplantation.
Boehringer Ingelheim prolonged global technology collaboration agreement with VTU Technology
Boehringer Ingelheim and VTU Technology, a leading contract research and development company, announced the renewal of their global Pichia pastoris technology collaboration agreement.
BOKU to open new Christian Doppler Laboratory for Glycerin Biotechnology
Glycerin is a side product of biorefineries based on plant oil, for example when producing biodiesel. The new laboratory is developing technologies for the microbial conversion of glycerin into value-added resources.
Eucodis participates in European ERA-IB project ChitoTex
The scope of the three-year project ChitoTex is to develop and produce new insect chitosan and chitosan based functional coatings for yarns and textile fabrics. Seven partners are involved.
IMBA: brain model highlighted in the "10 Breakthrough Technologies List"
The technology to grow three dimensional brain structures from human stem cells, has been named a top ten technology to solve difficult problems at the „MIT technology review“.
IMP to receive new research building
Boehringer Ingelheim will invest around 50 million Euros for the construction of new research premises for the Research Institute of Molecular Pathology (IMP) at the Vienna BioCenter.
mysugr: 4.2 million Euros for diabetes start-up
Roche Ventures (Basel), iSeed Ventures (San Francisco & Beijing) and XLHealth (Berlin) provide capital for the international growth of this Vienna-based specialist in digital health for diabetes.
Panoptes: ophthalmology company Panoptes Pharma and Mediolanum announce license agreement
Mediolanum acquires marketing rights to PP-001, a small molecule which is in preclinical development as next generation treatment for several inflammatory eye diseases including non-infectious uveitis.
Sanochemia Pharmazeutika AG: positive phase IIb results for Vidon®
Using Vidon® (PVP-Hypericin) for detecting non-muscle invasive bladder cancer (NMIBC) turned out to be superior to standard detection methods. No severe adverse side effects have been reported.
Siemens researchers develop lab on a chip
In collaboration with AIT, Siemens is developing a new analysis tool that involves placing and monitoring living cells on a chip. It shall make it possible to predicting how patients will react to therapeutic measures.
Themis Bioscience’s Chikungunya vaccine study results published in The Lancet Infectious Diseases
A phase I trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability.
TissueGnostics technology significantly contributes to phase I study published in Nature
In this publication a highly successful new treatment method for psoriasis is introduced. The TissueFAXS technology plays a central role in the observer-independent data acquisition performed for the phase I trial.
Valneva reported significantly improved preliminary full year 2014 results
Revenues and grants amounted to 42.4 million Euros. Strong Q4 IXIARO®/JESPECT® product sales resulted in FY 2014 net sales revenues of EUR 28.1 million.

Read more news at www.lisavienna.at.

LISAvienna NEWS and EVENTS

This year, you will see us working on the new edition of the Vienna Life Science Report. We invite you to support us by contributing your data and texts to the Austrian statistics and directory edited by aws and Biocom on behalf of BMWFW. To make things easy for you, information provided by Vienna-based organizations will also be incorporated in the Vienna Report. Please contact Brigitte Tempelmaier if you do not receive the corresponding questionnaire by mid April.

For medical device companies: Be invited to join IN3 EuroMedtech, June 10-11, 2015 in Vienna. Get in touch with Martin Mayer when interested in special conditions for registering for 2 days full of learning and partnering opportunities with corporate acquires, strategic investors and top innovators.
Interested in profiting from the MedTec Summer Academy? Please contact us to make the most of this opportunity to get in touch with talented students interested in your day-to-day technological challenges.

For biotechnology companies: We look forward to checking out business opportunities in Singapore and China together. Please contact Jürgen Fuchs for details.
Mark your calendar

Business Treff: How medtech companies best prepare for partnering events like IN3 EuroMedtech in Vienna
April 29, 2015, 2:30 p.m.- 6 p.m.
aws, Walcherstrasse 11A, 1020 Vienna

Save the date: Business Treff at the University of Veterinary Medicine, Vienna
October 7, 2015, 6 p.m.
University of Veterinary Medicine, Vienna, Veterinärplatz 1, 1210 Vienna
Meet LISAvienna

HIMSS15
Chicago, April 12-16, 2015

conhIT – Connecting Healthcare IT
Berlin, April 14-16, 2015

WKO Austrian Showcase Biotech/Pharma
Singapore and Shanghai, May 10-18, 2015

CMEF Spring 2015
Shanghai, May 15-18, 2015
 

Latest Publication

Vienna is Austria’s hot spot for cancer research and product development. Chemiereport updates you on new therapeutical approaches in the pipelines of Apeiron Biologics AG, Boehringer Ingelheim, Biomedical International R+D GmbH and Tube Pharmaceuticals GmbH.

Enjoy reading!
 

More LISAvienna events are available at www.lisavienna.at

FUNDING and SUPPORT Opportunities

aws: Bringing high-tech to life
The integrated financial aid program offered by aws provides assistance for business ventures in technology sectors exhibiting high potential for growth and great innovative strength. Apply for your tailormade funding scheme!

aws PreSeed
aws provides assistance to high-tech companies exhibiting a high level of technological sophistication in the pre-formation phase. Subsidies in the amount of up to 200,000 Euros may be granted and are paid out in accordance with a “milestone concept”.

aws Seedfinancing
aws provides assistance for the formation and expansion of high-tech companies, and also for the founding of new universities and non-university research facilities. The amount of this conditionally repayable subsidy may be as much as 800,000 Euros.

OPEN CALLS and DEADLINES to remember

March 23: Deadline for “Benefit – demographic change“ at FFG
March 26: Horizon 2020 “Biotechnology“ deadline
March 26: Horizon 2020 “Nanotechnologies, advanced materials and production“ deadline
March 30: ERACoSysMed with focus on „European Research Projects to demonstrate the feasibility and benefits of systems medicine"
March 30: Vienna Business Agency Program „Innovation“
April 27: Deadline for WWTF's Cognitive Sciences Call 2015
April 28: Expected deadline for submitting pre-proposals at the Joint Programming Initiative "A Healthy Diet for a Healthy Life" - Joint Action Intestinal Microbiomics
April 29: Cut-off date “Fast Track to Innovation - Pilot”

Find additional funding and support opportunities at www.lisavienna.at

EVENTS in Vienna

GPMed: Die Behörde als Industrieberater – von „Scientific Advice“ zu „Patient Access“

March 26, 2015, 3-6 p.m., AKH Wien, Hörsaalzentrum, Ebene 8, Hörsaal 3, Währinger Gürtel 18-20, 1090 Vienna

“The Fountain of Youth” Symposium, PACT – Platform for Advanced Cellular Therapies

April 13-14, 2015, University of Veterinary Medicine, Vienna, Festsaal, Veterinärplatz 1, 1210 Vienna

„Life Science: Patentportfolio als Basis zum Geschäftserfolg“

April 15, 2015, 2:30 p.m., Austria Wirtschaftsservice Gesellschaft mbH, Walcherstraße 11A, 1020 Vienna

Innovating for Patients

April 25, 2015, 6 p.m., Landtmann‘s Bel-Etage, Oppolzergasse 6, 1010 Vienna
For more events be invited to www.lisavienna.at.
Your news placed here: Vienna-based organizations are invited to e-mail news and press releases to news@LISAvienna.at to contribute to LISAvienna's digital and print media.
Copyright © LISAvienna 2015, All rights reserved.

Our mailing address is: office@LISAvienna.at

unsubscribe from this list    update subscription preferences
 
LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.